



Press Release

Poxel to Report 2023 First Half-Year Results and host a video conference on September 26, 2023

LYON, France, September 7, 2023 – POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including rare metabolic disorders and non-alcoholic steatohepatitis (NASH) , today announced that it will report its financial results for the Half-Year 2023 on **Tuesday, September 26, 2023**.

The management team will host a video conference call on September 26, 2023, in French at 1:00 pm CEST, and in English, at 8:30 am EDT (New York time) / 2:30 pm CEST (Paris time) to discuss the financial results and provide a corporate update.

Registration for the video conference call in English is available on the following link: <https://app.livestorm.co/newcap-1/presentation-of-poxels-2023-half-year-results?type=detailed>

A replay of the video conference will be available after the event on Poxel's website in the [Investors section / Company Info / Corporate Presentation](#).

About Poxel SA

Poxel is a **clinical stage biopharmaceutical company** developing **innovative treatments for chronic serious diseases with metabolic pathophysiology**, including **non-alcoholic steatohepatitis (NASH)** and rare disorders. For the treatment of NASH, **PXL065** (deuterium-stabilized *R*-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of **PXL770**, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). **TWYMEEG®** (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan, China, and eleven other Asian countries. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: www.poxelpharma.com





Contacts - Investor relations / Media

Aurélie Bozza
Investor Relations & Communication Senior Director
aurelie.bozza@poxelpharma.com
+33 6 99 81 08 36

NewCap
Nicolas Fossiez, Aurélie Manavarere / Arthur Rouillé
poxel@newcap.eu
+33 1 44 71 94 94